Paul A Mahon sold $4.7M of UTHR
EVP & GENERAL COUNSEL at UNITED THERAPEUTICS Corp. 8,300 shares at an average of $564.95, traded Oct 1, 2026, filed Oct 1, 2026.
Score components
- +15RoleOfficer
- +25Trade size$4.7M at market
- +5Share of holdings soldSold 16% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001231589-26-000021, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | MOption exercise Common Stock10b5-1 | +8,300 | $146.03 | $1.2M | 53,472 | 11 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -880 | $558.30 | $491k | 52,592 | 11 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -1,480 | $560.19 | $829k | 51,112 | 11 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -780 | $561.87 | $438k | 50,332 | 11 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -1,480 | $563.09 | $833k | 48,852 | 11 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -400 | $566.41 | $227k | 48,452 | 11 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -720 | $567.76 | $409k | 47,732 | 11 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -739 | $569.15 | $421k | 46,993 | 11 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -838 | $570.90 | $478k | 46,155 | 11 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -823 | $572.25 | $471k | 45,332 | 11 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -160 | $573.15 | $92k | 45,172 | 11 d ago |
| Oct 1, 2026 | MOption exercise Stock Optionderivative10b5-1 | -8,300 | $0.00 | $0 | 39,240 | 11 d ago |
Related signals
Other insiders at UNITED THERAPEUTICS Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.5M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $3.9M 7,580 shares | -2% | |
| 38Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $1.1M 1,920 shares | -1% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $4.5M 9,500 shares | -3% | |
| 30Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $4.6M 9,500 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.